Britain holds a unique position in the global medical cannabis industry as one of the world’s largest exporters and producers of cannabis for scientific and medical purposes. This booming industry positions the UK as a key player internationally. However, the paradox is stark: despite this significant role, fewer than five NHS patients were receiving medical cannabis prescriptions as of August 2023.

This contradiction highlights an ongoing issue in the UK healthcare system. Despite medical cannabis being legal for prescription since 2018, access remains extremely limited within the NHS. While private clinics such as Mamedica offer prescriptions, NHS patients continue to face barriers including restrictive guidelines, conservative prescribing practices, and limited clinical education.

Why does the NHS not use Medical Cannabis More?

Medical cannabis has been proven effective for a variety of conditions, including chronic pain, epilepsy, and multiple sclerosis. Yet, the stigma around cannabis, combined with bureaucracy, keeps many patients from obtaining these treatments. Patients are left frustrated, particularly when they are aware that Britain’s cannabis output is benefiting other countries more than its own citizens.

Mamedica’s Take

Mamedica Founder & CEO Jon Robson leads a brand new conversation with ITV News, regarding the benefits of cannabis legalisation alongside the difficulty presented with NHS systems. With a major shift in public perception and greater acceptance of medical cannabis across the healthcare sector, Mamedica strives to spearhead the movement towards more holistic healthcare.

In Jon’s discussion with ITV, he stated “In theory, the NHS should be prescribing medical cannabis for three conditions; MS, epilepsy and nausea and vomiting caused by chemotherapy…Unfortunately the reality is that NHS doctors follow Nice (National Institute for Health and Care Excellence) guidelines which, although permit prescribing of medical cannabis for these conditions, provide very limited access and scope for doctors to use their discretion”.

“We currently have north of 50,000 patients in the market expected to rise to 300,000 plus by 2028,” he added.

How Mamedica Can Help

If you’re interested in experiencing the benefits of medical cannabis, Mamedica provides holistic support for a number of conditions.

If you would like to start your journey with Mamedica, you can check your eligibility here.